Interestingly, it was also recently revealed that VEGFR2-targeted therapy influenced a novel VEGFR2 and EphA2 association in NSCLC cells with a downstream effect on RSK as well as on pEphA2 S897 signaling, invasion and metastatic potential [34]. This evidence concerns the gene EPHA2 and non-small cell lung carcinoma.